Dossier04 source register
FTC insulin complaint announcement, 20 September 2024
FTC allegations; approximately 80% of US prescriptions administered by Big Three; not a final liability finding.
Read the primary sourceFTC Docket 9437 / status checked 24 October 2026
Pending docket; ESI settlement announced February 2026; Caremark agreement July 2026; Optum withdrawn from adjudication June 2026 for consideration of proposed consent. Do not call these final judgments.
Read the primary sourceFTC second interim staff report, January 2025
Selected specialty generic study, 2017–2022: more than $7.3B dispensing revenue above estimated acquisition cost; not net profit or all drugs.
Read the primary sourceFTC specialty generic report and methodology
NADAC is a benchmark; reimbursement, affiliated pharmacy concentration and spread pricing are distinct measures.
Read the primary sourceSenate Finance bipartisan insulin investigation, January 2021
Historical documents and contract incentives; not a current retail price list.
Read the primary sourceFDA Generic Drug Facts
Same active ingredient, strength, dosage form, route and required performance; prescriber/pharmacist assesses suitability.
Read the primary sourceCMS rights when not using insurance
Good faith estimate scope; not an automatic right to rewrite every bill.
Read the primary sourceCMS patient-provider dispute resolution
Uninsured/self-pay eligibility, at least $400 above provider estimate, 120-day window, $25 fee; verify current rules.
Read the primary sourceMedicare Part D costs
Plan stages and cost sharing vary; cash purchases and plan accumulators must be checked separately.
Read the primary sourceRespondents’ position in FTC-filed collateral complaint, November 2024
Respondent filing disputes FTC theory, emphasizes manufacturer list-price setting and negotiated concessions. It is an advocacy filing, not an agency finding.
Read the primary sourceFTC first interim PBM staff report, July 2024
Concentration, parent/affiliate map, formulary and independent-pharmacy contract concerns; staff findings, not a final liability judgment.
Read the primary source